BOSTON, MA, Remedium Bioa biotechnology company developing, has closed more than $2.3M in its expanded seed round financing led by Sherwood Ventures.
Remedium Bio, Inc., a biotechnology company developing novel gene therapies, has closed more than $2.3M in its expanded seed round financing.
Funding from the raise is being used to study Remedium's lead product, a single-injection gene therapy potentially capable of reversing cartilage loss, in a collaboration with Tufts University School of Medicine scientists researching rheumatic disorders.
The financing was led by Sherwood Ventures and included participation from, LongevityTech.Fund, Primo Medical Group, Angel Star Ventures, Apis Health Angels, MicroVentures, and Guindy Alumni Angels.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about